The investment has been made through Caixa Innvierte BioMed II, a vehicle managed by Caixa Capital Risc, the venture capital arm of "la Caixa". The fund is driven by "la Caixa" and the Centro para el Desarrollo Tecnológico Industrial (Centre for Industrial Technological Development, CDTI) under the framework of the Innvierte Programme and has minority participation from the Institut Català de Finances.
Inbiomotion: Predicting bone metastasis
Inbiomotion is a personalized medicine company based in Barcelona. It develops biomarkers that predict bone metastasis to improve cancer patients’ quality of life. Founded in 2010 by Dr. Roger Gomis, it is a spin-off of IRB Barcelona and ICREA research institutions.
Inbiomotion’s unique diagnostic assay is based on a highly selective single gene biomarker. It can predict at an early stage a patient’s risk of bone-specific metastases from primary tumors. The selectivity of the lead biomarker has the potential to advance the clinical standard of care using personalized medicine.